Thursday, 17 November 2011

Research: Blood Stem cells in advanced MS

Bowen et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2011 [Epub]


The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS).


Methods: Total body irradiation, cyclophosphamide and anti-thymocyte globulin(to kill T cells) were followed by transplantation of autologous, CD34-selected peripheral blood stem cells. Neurological examinations, brain magnetic resonance imaging and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n=26, mean Expanded Disability Status Scale (EDSS)=7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT.




Results: The 72-month probability of worsening 1.0 EDSS point was 0.52 (95% confidence interval, 0.30-0.75). Five patients had an EDSS at baseline of 6.0; four of them had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable for as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment.


Conclusions: HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.


"Impressive results, pity the short-term risks associated with bone marrow transplantation are so high. In some registries the risk of dying from a complication of bone marrow transplantation is ~5%. Are you prepared to take these risk?"

3 comments:

  1. How can one mitigate some of the risks?
    Is there a risk stratification model as for Tysabri (JCV, previous immunosupression...)

    ReplyDelete
  2. I had the wonderful luck to have one son with acute myloid leukaemia and another with MS. My son with AML had a BM transplant which he sailed through with no problems (although he had had some terrible times with the initial induction and consolidation treatments), but I think Stella on her blogspot on the MSRC website who has undergone SC transplant has lost some fingers after she developed sepsis. I don't think anyone can say which way it will go, opportune infections can happen when you've got no immune system. So it should only be attempted in a top class haemo dept.

    ReplyDelete
  3. Ret: "How can one mitigate some of the risks?"

    I agree with Anon 2's comment; it should only be attempted in a top class unit. The mortality rate in top unit is ~0.5% (1 in 200). The JCV testing is not really relevant to bone marrow transplantation.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.